The statistical findings also show that high BMI resulted in over 150,000 lost years of life across all demographic groups in a single year. The comprehensive epidemiological investigation examined underlying causes of death to determine how elevated body mass index contributes to chronic health conditions. Research findings identified cardiovascular complications as the primary contributor to mortality, with coronary heart diseases accounting for 2,009 deaths. Neurodegenerative disorders represented the second largest category, as Alzheimer disease and other forms of dementia were linked to 1,652 deaths. Additionally, cerebrovascular diseases were cited in 1,171 deaths, alongside significant contributions from chronic kidney disease and various digestive cancers.

The study will operate at three Canadian sites and enroll about 80 healthy adults. Researchers will assess the vaccine’s safety, tolerability and ability to produce an immune response. The trial will not determine whether the vaccine prevents infection because Phase 1 studies focus on early safety data. The Coalition for Epidemic Preparedness Innovations has committed up to $50 million for preclinical work, the trial and production of additional research doses.